Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \quad Origin: Appendix 5 \quad Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13 \\$ 

Name o	fentity		
Austra	Australian Mines Limited		
ABN			
68 o73	914 191		
We (th	ne entity) give ASX the following	information.	
	1 - All issues		
You mus	st complete the relevant sections (attach	sheets if there is not enough space).	
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary fully paid shares	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	235,294,118 shares	
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary fully paid shares	

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.085 per Share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ul> <li>To continue trial mining and complete bank feasibility study of the Sconi Cobalt Nickel Scandium Project;</li> <li>To accelerate drilling at Flemington Project.</li> <li>See announcement to market dated 6 November 2017</li> </ul>
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in</i> relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	22 November 2016 and 13 November 2017
6c	Number of *securities issued without security holder approval under rule 7.1	87,610,596

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	147,683,522	
		271	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
		T/	
6g	If *securities issued under rule 7.1A,	Yes.	NT
	was issue price at least 75% of 15 day VWAP as calculated under rule	Issue Date:	14 Nov 2017
	7.1A.3? Include the +issue date	Issue price	\$0.085
	and both values. Include the	75% of 15-day VWAP	\$0.0646
	source of the VWAP calculation.	   15-day VWAP calculati	on Courage
		Argonaut Securities Pt	
		riigonaat securities i t	y Limited
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	All shares were issued	for cash consideration
6i	Calculate the entity's remaining	268,333,337 under rule	7.1
	issue capacity under rule 7.1 and	89,612,433 under rule 7	-
	rule 7.1A – complete Annexure 1		
	and release to ASX Market		
	Announcements		
7	<sup>+</sup> Issue dates	13 November 2017	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		N l	+C1
0	N 1 111 6 111	Number	+Class
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the *securities in section 2 if applicable)	2,608,253,672	Ordinary fully paid

<sup>+</sup> See chapter 19 for defined terms.

		Number	+Class
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	Nil	Not applicable
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Not applicable	
Part 2	2 - Pro rata issue		
11	Is security holder approval required?		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the <sup>+</sup> securities will be offered		
14	*Class of *securities to which the offer relates		
15	<sup>+</sup> Record date to determine entitlements		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17	Policy for deciding entitlements in relation to fractions		
18	Names of countries in which the entity has security holders who will not be sent new offer documents		
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.		

<sup>+</sup> See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements in full through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

<sup>+</sup> See chapter 19 for defined terms.

32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	
	3 - Quotation of securities ed only complete this section if you are applying for qu	uotation of securities
34	Type of *securities (tick one)	
(a)	X +Securities described in Part 1	
(b)	*	rowed period, partly paid securities that become fully paid, ends, securities issued on expiry or conversion of convertible
	es that have ticked box 34(a) tional securities forming a new class of	securities
Tick to docume	to indicate you are providing the information or nents	
35	1 1	s, the names of the 20 largest holders of the er and percentage of additional *securities
36	If the *securities are *equity securitie	s, a distribution schedule of the additional nolders in the categories
37	A copy of any trust deed for the additi	onal <sup>+</sup> securities

<sup>+</sup> See chapter 19 for defined terms.

Entities	s that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)		

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Benjamin Bell Date: 14 November 2017 (Director)

Print name: Benjamin Bell

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B - Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	1,183,672,272	
<ul> <li>Add the following:         <ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul> </li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period         <ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as</li> </ul> </li></ul>	89,722,078 – issued in February 2017 38,456,951– issued in February 2017 60,745,071– issued in February 2017 249,564,145 - rights issue and placement 7 and 10 April 2017 9,750,000 – placement 12 April 2017 475,538,678 – convertible notes 13 April 2017 32,177,022 – placement 27 April 2017 233,333,337 – issued 11 September 2017	
separate line items  Subtract the number of fully paid  †ordinary securities cancelled during that 12 month period	Nil	
"A"	2,372,959,554	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
<b>Multiply</b> "A" by 0.15	355,943,933	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	87,610,596 this appendix 3B	
Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix</li> </ul>		
3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
"C"	87,610,596	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	355,943,933	
Note: number must be same as shown in Step 2		
Subtract "C"	87,610,596	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	268,333,337	

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" 2,372,959,554  Note: number must be same as shown in Step 1 of Part 1		
"D"  0.10  Note: this value cannot be changed		
<b>Multiply</b> "A" by 0.10 237,295,955		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	147,683,522 this Appendix 3B	
	147,683,522	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
237,295,955	
147,683,522	
89,612,433	

<sup>+</sup> See chapter 19 for defined terms.